Cassava Sciences Announces New Chief Medical Officer
In a significant development for the company, Cassava Sciences, Inc. (NASDAQ: SAVA) has appointed Dr. Joseph Hulihan as its new Chief Medical Officer (CMO). Dr. Hulihan's extensive expertise and innovative approach to clinical development are set to bolster Cassava's efforts in advancing treatments for central nervous system (CNS) disorders, particularly for conditions resulting from Tuberous Sclerosis Complex (TSC).
Dr. Hulihan's Background and Expertise
With over 25 years of rich experience in the pharmaceutical sector, Dr. Hulihan holds a longstanding reputation for advancing therapeutics targeting neurological disorders, including epilepsy. He has previously served as CMO for Marinus Pharmaceuticals, contributing significantly to the development of ganaxolone, a promising treatment for seizure disorders. Additionally, Dr. Hulihan has held senior roles in medical affairs within renowned companies like Janssen Pharmaceuticals, enhancing his skill set in the clinical development landscape.
His Role at Cassava
At Cassava, Dr. Hulihan will be instrumental in guiding the clinical strategy for simufilam, a novel treatment currently in development for TSC-related epilepsy. As Cassava prepares to launch its clinical study for simufilam, Dr. Hulihan's insights and connections to the TSC community will be invaluable. Rick Barry, President and CEO of Cassava, expressed excitement about the collaborative potential that Dr. Hulihan brings to the organization.
Simufilam: A New Hope for TSC-Related Epilepsy
Simufilam is an investigational small molecule that aims to modulate the filamin A protein, believed to play a crucial role in neuronal development and function. The upcoming clinical study for simufilam is anticipated to take place in the first half of 2026, marking a pivotal moment for Cassava as it seeks to offer a first-in-class treatment for individuals affected by TSC-related epilepsy.
What This Means for Patients and Families
The appointment of Dr. Hulihan reflects Cassava's commitment to improving the lives of patients grappling with CNS disorders. With a dedicated focus on TSC-related epilepsy and ongoing research efforts, Cassava is poised to make significant advances in the treatment landscape. Families affected by TSC can look forward to new therapeutic options on the horizon, backed by Dr. Hulihan's depth of knowledge and experience.
About Cassava Sciences, Inc.
Cassava Sciences, Inc. is dedicated to pioneering treatments for CNS disorders, with a primary focus on TSC-related epilepsy among other indications. The company, headquartered in Austin, Texas, is committed to utilizing insightful clinical strategies to bring innovative solutions to patients. With Dr. Hulihan leading the clinical development team, Cassava is well-positioned to navigate the complexities of drug discovery and development.
Frequently Asked Questions
Who is Dr. Joseph Hulihan?
Dr. Joseph Hulihan is the newly appointed Chief Medical Officer of Cassava Sciences, with extensive experience in clinical development for neurological disorders.
What is simufilam?
Simufilam is an investigational treatment being developed by Cassava Sciences aimed at treating TSC-related epilepsy.
When is the clinical study for simufilam expected to begin?
The clinical study for simufilam is anticipated to commence in the first half of 2026.
What is Tuberous Sclerosis Complex (TSC)?
Tuberous Sclerosis Complex is a genetic disorder that causes benign tumors to grow in various organs, including the brain, and can lead to epilepsy.
How can I learn more about Cassava Sciences?
For more information about Cassava Sciences and its research initiatives, visit their official website.
